Clinical Trials
6 trialsNCT01313559 2025-04-30
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
Thomas Jefferson University
Phase 2 Terminated
NCT04826432 2024-02-08
PASIREOCHIP
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Terminated
NCT01372618 2017-12-27
Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor
NYU Langone Health
Phase 1/2 Terminated
NCT00929669 2017-11-28
LAR
University of Pennsylvania
Phase 2 Terminated
NCT01617733 2016-11-02
Pasireotide Therapy in Patients With Nelson's Syndrome
Sheffield Teaching Hospitals NHS Foundation Trust
Phase 2 Terminated
NCT00813592 2014-06-11
Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma
University of Utah
Phase 2 Terminated